Overview

Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma

Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
Zevalin may be an effective therapy for newly diagnosed marginal zone lymphoma (MZL).
Phase:
Phase 2
Details
Lead Sponsor:
University of Miami
Treatments:
Antibodies, Monoclonal
Rituximab